Gradient Bioconvergence (CEO Jin-Geun Lee) announced that it will participate in the '2025 American Society of Clinical Oncology (ASCO 2025)' held in Chicago, USA from the 30th to June 3rd (local time).
At this conference, Gradient Bioconvergence will present its latest research results on 'GBC-11004', a new treatment target for non-small cell lung cancer, in a poster presentation, and will operate an exhibition booth to introduce patient-derived organoid (PDO) banking and AI-based target discovery platform, while seeking opportunities for collaboration with global pharmaceutical and bio companies.
'GBC-11004' is a novel kinase discovered by Gradient Bioconvergence through the world's largest PDO big data and AI-based platform, and shows the characteristic of being overexpressed in non-small cell lung cancer patients who are resistant to third-generation EGFR inhibitors. The company effectively derived the resistance gene that was difficult to identify with existing next-generation sequencing (NGS) analysis alone, and proved that GBC-11004 is effective as a therapeutic target by performing CRISPR-based gene editing and PDO-based drug evaluation.
In addition, the individual exhibition booths operated in conjunction with this will showcase over 900 types of PDO banking and target and biomarker discovery technologies using the company’s AI models, and will discuss related commercialization with various global partners. The company added that it expects the immune cell and vascular cell co-culture model that precisely embodies the actual tumor microenvironment and the discovery of candidate substances through AI technology to receive great interest from industry insiders.
“We expect that through this conference, we will be able to specifically introduce our platform technology that meets various collaboration needs,” said Jin-Geun Lee, CEO of Gradient Bioconvergence. “Our precise target discovery and verification capabilities based on AI and actual patient-derived data will be a strong differentiator in global joint research.”
- See more related articles
You must be logged in to post a comment.